【大摩上调Apellis Pharmaceuticals(APLS.US)目标价至26美元 维持“持有”评级】智通财经A

智通财经
Jul 07, 2025
【大摩上调Apellis Pharmaceuticals(APLS.US)目标价至26美元 维持“持有”评级】智通财经APP获悉,摩根士丹利分析师Judah Frommer发表研报,将Apellis Pharmaceuticals(APLS.US)目标价从25美元上调至26美元,同时维持“持有”评级。Frommer表示,这一评级是基于该公司市场地位及近期财务战略所作出的判断。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10